Report Shows Nearly 50% of Biopharma Companies Heavily Use AI
AI has shifted from a side topic to a central theme in the biopharma world. Over the past year, multibillion-dollar AI collaborations have become routine, chipmakers have found new demand in drug research, and industry events have turned into forecasting sessions about how machine learning might reshape the lab. To get a reality check, Endpoints Signal, a data and insight service created by Endpoints News, asked its readership how AI is affecting their actual work. The survey explored where the technology is helping, where it falls short, and how views differ among researchers, corporate leaders, and the investors who support…